Home · Solutions · UpperNose™

UpperNoseTM

UpperNose™ helps innovators rapidly assess, develop and manufacture nasal drug products through an integrated formulation, device selection and GMP development pathway.

Speak to our experts

From feasibility to clinical supply, UpperNose™ combines formulation development, device expertise, analytical services and GMP manufacturing to help innovators rapidly assess and develop nasal drug products.

why choose uppernose

Clinical-ready formulation strategy in 12 weeks.

Rapid assessment programmes help identify the most suitable development pathway, reducing unnecessary experimentation and enabling efficient progression towards clinical evaluation.

Our scientists bring extensive experience across liquid and dry powder nasal formulations, supporting the unique challenges associated with nasal delivery systems and device selection.

Why choose UpperNose™?

Developing a successful nasal drug product requires expertise in formulation, device selection, analytical testing and GMP manufacture. UpperNose™ provides an integrated pathway that helps innovators move from concept to clinic faster.

The ability to self-administer small molecules, biologics and vaccines is highly attractive yet the knowledge and expertise necessary to rapidly develop products for this alternative delivery route remains limited in the CDMO space. To meet this growing demand, Upperton has developed UpperNose™, a unique nasal product development platform. Our aim is to make it easier and faster for small and mid-sized innovators to access the knowledge and capabilities necessary for the successful development of nasal dosage forms.

The UpperNose™ platform can be applied to liquid and dry powder formulations and utilises the knowledge and expertise of the highly experienced Upperton scientific team to develop your molecule in an efficient and timely manner.

Working closely with our clients, we identify the most time/cost effective development programme in just 12 weeks to facilitate early, smooth passage of our customer’s molecule from early-stage development into clinical trials. Typically we will take our customers through a series of well-established development steps although in reality, some of these can be combined or omitted depending on the dosage form required.

When to use UpperNose™

UpperNose™ is ideally suited to:

Nasal spray development
Nasal powder development
Enabling nose-to-brain delivery
Vaccine development
Peptides and biologics
Novel CNS therapies
Fast progression into clinical studies

What You Receive

Nasal formulation strategy
Device recommendation
Development pathway recommendation
Clinical-ready programme plan
Analytical and stability strategy
GMP manufacturing roadmap

UpperNose™

Applications

Local delivery to the nasal membranes (e.g. for vaccines, antivirals, prophylactics)
Systemic delivery by absorption into the bloodstream (e.g. for fast action whilst avoiding first pass metabolism)
Direct delivery into the brain (transcending the blood brain barrier for treatment of neurodegenerative and psychological disorders)

Benefits of UpperNose™

Generating scientific and regulatory data to get you into the clinic with a high degree of confidence. Data to make informed decisions and support regulatory submissions.
Driven by experts and led by science. Our highly experienced team will work with you to overcome the unique needs of your molecule.
Working with customer’s own or commercially available nasal delivery devices. Ensuring the successful development of your drug either at the development or clinical trial phase.
Laying the foundation for commercial success. We will help you establish a clear path that could take you all the way to commercial success. Reach your milestones faster without compromising quality.

A STRUCTURED ROUTE TO CLINICAL EVALUATION

Develop target product profile
e.g. anticipated dose, frequency of dosing.

Pre-formulation / Stability Screening.

Selection of Dosage Form.

Formulation and process development to support regulatory submissions, toxicology evaluation.

Manufacture of clinical batches.

The UpperNose™ Development Pathway

UpperNose™ is Upperton’s integrated nasal drug development platform, designed to accelerate the journey from molecule to clinical evaluation. Combining formulation expertise, device selection, analytical development and GMP manufacturing within a single CDMO partner, UpperNose™ helps companies rapidly assess the potential of nose-to-brain and systemic nasal drug delivery approaches.

Clinical-ready nasal formulation in as little as 12 weeks, enabling rapid proof-of-concept generation and early programme de-risking.
Integrated formulation development, device selection, analytical development and GMP manufacturing within a single CDMO partner.
Progress from initial formulation design to first-in-human clinical supply in as little as 24 weeks.
Supports the development of peptides, biologics, small molecules and novel CNS therapies.

Whether developing peptides, biologics, small molecules or novel CNS therapies, UpperNose™ provides a fast, flexible and scientifically driven route to clinic, helping innovators realise the full potential of intranasal drug delivery.